ArticleHealth science reports2026
Comparative Efficacy and Safety of Antihypertensive Strategies in Diabetic Kidney Disease: Protocol for an Update of a Systematic Review and Component Network Meta-Analysis.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Chronic kidney disease (CKD) is a significant global contributor to morbidity and mortality, with hypertension and diabetes mellitus remaining its primary causes. Effective antihypertensive treatment is a key modifiable strategy to improve outcomes in this population. However, the emergence of novel therapies, together with uncertainties over the synergistic effects and safety of combining antihypertensive drug classes, has left optimal blood pressure management in CKD and diabetes unclear. We present a study protocol for an updated systematic review and component network meta-analysis, which aims to answer which blood pressure therapies in adults with diabetes mellitus who have or are at risk of CKD are most efficacious in improving survival and reducing the risk of end-stage kidney disease. Methods: This protocol was developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines and has been registered in the PROSPERO registry (with the identifier: CRD42021286617). Updating a previous review, database searches will be performed in Cochrane Renal Group's specialized register; Embase OVID SP; MEDLINE OVID SP and the Cochrane Central Register of Randomized Trials for randomized controlled trials that evaluate antihypertensive treatments in adults with both CKD and diabetes mellitus. We will include trials that evaluate one or more of the following treatments administered in any combination: (1) angiotensin-converting enzyme inhibitors; (2) angiotensin receptor blockers; (3) calcium channel inhibitors; (4) beta-blockers; (5) renin inhibitors; (6) alpha blockers; (7) diuretics; (8) endothelin inhibitors; (9) non-steroidal and steroidal mineralocorticoid receptor antagonists. Results: The primary outcomes are all-cause mortality and progression to end-stage kidney disease. Conclusions: This updated systematic review and component network meta-analysis will incorporate advanced novel analytical techniques to produce the first clinically meaningful hierarchy of antihypertensive interventions according to efficacy and safety in patients with CKD and diabetes mellitus, carrying implications for future clinical practice guidelines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.